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ABSTRACT 
Background & Objective:  Parkinson’s disease (PD) is the second most common Neurodegenerative 
disorder after Alzheimer’s disease. There are several surgical procedures for advanced PD, but amongst all 
deep brain stimulation has proven to be safest and effective. The objective of this study was to see the 
outcome of DBS for the treatment of PD in terms of improvement in MDS UPDRS over 5 years. 
Material and Methods:  44 patients were included in study from Oct 2014 to Sep 2019. History, 
examination was carried out, and preoperative MDS-UPDRS (Movement Disorder Society Unified Parkinson’s 
Disease Rating Scale) was recorded. Postoperative improvement in MDS-UPDRS score was assessed at first 
Programming, 2nd week, and 6th week and at 3rd month. 
Results:  At baseline the mean, the MDS – UPDRS (Part-I) score was 14.20 ± 0.61 and at the end of 3rd 
month, the mean score was 11.18 ± 0.47 respectively. At baseline the mean, the MDS – UPDRS (part-II) score 
was 18.99 ± 0.70 and at the end of 3rd month, the mean score was 13.01 ± 0.57, respectively. At baseline the 
mean, the MDS – UPDRS (part-III) score was 45.19 ± 0.90 and at the end of 3rd month, the mean score was 
25.15 ± 1.20 respectively. At baseline the mean, the MDS – UPDRS (part-IV) score was 10.18 ± 0.87 and at 
the end of 3rd month, the mean score was 3.85 ± 1.03, respectively. One patient developed post-operative 
ICH (intracerebral hemorrhage), which resolved after 1 month. 
Conclusion:  The Deep Brain Stimulation (DBS) is safe and effective in the management of PD. 
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INTRODUCTION 
Amongst neurodegenerative diseases, Parkinson’s 
disease is ranked second after Alzheimer’s 
disease. There are many contributing risk factors, 
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some are environmental and some genetic1.It 
manifests as bradykinesia, rigidity, resting tremor 
and postural instability.2 Prevalence of Parkinson’s 
disease (PD) is low in Asian countries, but 
universally it ranges from0.012 to 12.5% and the 
incidence ranges from 15 per hundred thousand 
to 328 per hundred thousand.2 
 The medical treatment options, which are 
available only providing the symptomatic relief, 
but do not affect neuronal loss.Most of these 
patients do not remain stable on these 
medications and they develop dyskinesias and 
motor fluctuations. Usually, thenon-motor 
symptoms do not respond well to dopaminergic 
replacement therapies.4 Patients with Parkinson's 
disease regularly have quick swings among 
versatility and idleness, and many react 
inadmissible to changes in pharmacological 
treatment.3 
 Advancements in Stereotactic technology 
have led to a lot of developments in the 
management of Parkinson’s disease.3 Previously, 
the surgical options available were stereotactic 
lesioning (Pallidotomy and Thalamotomy) having 
disadvantage of permanent lesioning. In 1987, the 
deep brain high frequency stimulation of the 
thalamus was experimented to treat tremors. In 
1993, it was tested for sub-thalamic nucleus to 
treat advanced cases of Parkinson’s disease.In 
Pakistan first Deep Brain stimulation surgery was 
conducted at Lahore General Hospital (LGH) in 
2013. High-frequency stimulation of the 
subthalamic nucleus has become the surgical 
therapy of choice.4 DBS is an effective surgical 
treatment for Parkinson’s disease on the other 
hand it may have some complications which are 
operation related, hardware related and 
stimulation related. 
 The target of choice for DBS is the 
subthalamic nucleus (STN), many studies, has 
underlined the efficacy of STN Deep Brain 
Stimulation (DBS). The Globus Pallidus is the 
second most frequent target, although supported
to a lesser extent by controlled studies.5 
 MDS-UPDRS representing a compound 
measure of the disease severity with different 
subscales. The four cardinal symptoms – rigidity, 
tremor, bradykinesia, and postural instability – are 
scored by the UPDRS part III, whereas mentation, 
mood, and behavior (part I), activities of daily 
living (part II), and dyskinesia (part IV) are scored 
separately. Higher values indicate more severe 
symptoms; thus, increasing values are connected 
exponentially with symptom severity. 
Standardized assessments are used by the vast 
majority of studies.6 
 
MATERIAL AND METHODS 
Study Design 
Prospective obstructive study. 
 
Inclusion Criteria 
From Oct 2014 to Sep 2019, 44 patients with 
advanced Parkinson’s disease were enrolled in the 
study from PINS (Punjab Institute of 
Neurosciences), Lahore. After endorsement from 
hospital ethical committee, all patients satisfying 
the inclusion criteria were included in the study. 
The procedure was explained and informed 
consents were taken from all the patients or 




Primary Parkinson’s disease, which is medically 
refractory (carbidopa 200 mg/day and Levodopa 
800 mg/day) for at least 6 months. We enrolled 
patient’s withno structural lesion on MRI Brain, 
and those who reported the absence of dementia. 
 
Excluding Criteria 
Patients were excluded who were with Atypical/ 
Secondary Parkinsonism and advanced 
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Proper history and examination were carried out, 
and preoperative MDS- UPDRS (Movement 
Disorder Society Unified Parkinson’s Disease 
Rating Scale), was recorded. Blood investigations 
via., CBC, LFTs, RFTs, APTT, and PT/INR was done. 




In the operation theatre, a stereotactic frame 
(Leksell G frame) was applied to the patient’s 
head.The patient was transferred to MRI 
department and MRI Brain is obtained. The 
images were then transferred to Surgi Plan/Frame 
link (as we are using two work stations in our 
department) workstation. The images were first 
defined, then looking on the mid-sagittal cuts 
anterior commissure and Posterior commissure 
was defined and AC-PC line was drawn between 
these two points. This acquired target was further 
confirmed by super imposing Shelton Brain 
digital brain atlas. Once the desired target was 
confirmed the path to hit that target was 
determined. The whole computerized calculation 
was printed and carried to the operation theatre 
for surgery. The Leksell frame was attached on 
head end of the OT table with an attachment to 
fix the head during surgery. Head end was lifted-
up to 30 degrees. Head shave of the patient was 
done. Arc and Rings were attached to the frame 
according to the calculations, and X, Y and Z of 
the frame were adjusted. Pyodine solution and 
local anesthetic solution were applied at the site 
for skin incision. A 14-mm bur hole was placed 
and dura opened. For STN, MER (Micro electrode 
Recording) is performed using the Microdrive, 
microelectrodes and Inomed Machine. The 
patient was evaluated by a neurologist for 
assessment of tremors/rigidity and any capsular 
side effects. The area of maximal therapeutic 
benefit was recorded and DBS lead is measured 
so that the distal contact lies just below the noted 
area. 
 The second stage of the operation was 
performed under general anesthesia. The 
proximal ends of the DBS leads connected, to an 
implantable pulse generator, which was placed in 
an infraclavicular subcutaneous pocket on right 
side of chest. The pre-op medications for 
Parkinsonism, which were stopped were restarted. 
A post op CT scan brain plain was performed to 
see the placement of leads and to see any 
complication. The patient was evaluated in the 
next morning and MDS-UPDRS noted. Patients 
were then discharged and asked to come after 
two weeks for stitch removal and programming. 
 
Programming 
IST programming was done two weeks after 
surgery in which voltage, Frequency and pulse 
width were adjusted to alleviate patient 
symptoms. The patient may need a couple of 
programming sessions. Programming sessions are 
conducted by a Neurosurgeon and a Neurologist 
at our Center. MDS-UPDRS noted at Post 
Programming, 2 weeks, 6 weeks and 3 months to 
see improvement in MDS-UPDRS score. 
 
Data Analysis 
Data was statistically analyzed using SPSS 26. 
Variables were identified. Simple descriptive 
statistics were used for analysis of 
demographic variables. Mean and standard 
deviations were calculated for age, 
frequencies and percentages were 
determined for qualitative variables that are 
gender, post-operative complications, 
mortality, morbidity and hospital stay. Paired 
t-test were applied. 
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The mean age of patients was 
67.07 ± 9.45 years with minimum 




There were 29 (65.9%) male and 
15 (34.09%) female cases with 
male to female ratio as 2:1. 
 
Outcome 
At baseline, the mean MDS – 
UPDRS (part-I) score was 14.20 ± 
0.61, at 2nd week, the score was 
13.78 ± 0.56, at 6th week the 
score was 12.72 ± 0.68 and at 
the end of 3rd month, the mean 
score was 11.18 ± 0.47, 
respectively. 
 On applying paired sample t-
test, a significant reduction in 
MDS-UPDRS score was found 
when compared at different 
follow-ups, p-value ≤ 0.001. 
Overall, the decrease in MDS-
UPDRS score (Part-I) was 
statistically significant. 
 At baseline, the mean MDS – 
UPDRS (part-II) score was 18.99 
± 0.70, at 2nd week the score was 
18.58 ± 0.84, at 6th week the 
score was 15.93 ± 0.57 and at 
the end of 3rd month the mean 
score was 13.01 ± 0.57 
respectively. There was 
significant reduction in MDS-
UPDRS score when compared 
with different follow-ups, p-value 
< 0.05 except baseline versus 2
 
Table 1: Comparison of MDS-UPDRS (Part-I) score at different follow-
ups. 
MDS-UPDRS (part-I) Mean S.D Range Minimum Maximum 
At baseline 14.20 0.61 1.90 13.10 15.00 
At 2 weeks 13.78 0.56 2.20 12.80 15.00 
At 6 weeks 12.72 0.68 2.00 11.50 13.50 
At 3 month 11.18 0.47 1.30 10.50 11.80 
 
 
Table 2: Comparison of MDS-UPDRS (Part-I) score at different follow-
ups (F-test value =22302.013). 
MDS-UPDRS (part-I) t df p-value 
Baseline versus 2 weeks   4.063 14 0.001 
Baseline versus 6 weeks   7.320 14 < 0.001 
Baseline versus 3 months 14.363 14 < 0.001 
2 weeks versus 6 weeks   4.284 14 0.001 
2 weeks versus 12 months 13.560 14 < 0.001 





Figure 1: Graphical Comparison of MDS-UPDRS (Part-I) score at different 
follow-ups. 
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weeks, p-value > 0.05. Overall, 
the decrease in MDS-UPDRS 




Table 3: Comparison of MDS-UPDRS (part-II) score at different follow-
ups. 
MDS-UPDRS (part-II) Mean S.D Range Minimum Maximum 
At baseline 18.99 0.70 1.90 18.10 20.00 
At 2 weeks 18.58 0.84 2.70 17.30 20.00 
At 6 weeks 15.93 0.57 1.90 15.00 16.90 
At 3 month 13.01 0.57 1.70 12.20 13.90 
 
 
Table 4: Comparison of MDS-UPDRS (part-II) score at different follow-
ups (F-test = 26070.056). 
MDS-UPDRS (part-II) t df p-value 
Baseline versus 2 weeks   1.629 14 0.126 
Baseline versus 6 weeks 16.196 14 < 0.001 
Baseline versus 3 months 23.568 14 < 0.001 
2 weeks versus 6 weeks 12.720 14 < 0.001 
2 weeks versus 12 months 19.697 14 < 0.001 
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 At baseline, the mean MDS – 
UPDRS (part-III) score was 45.19 
± 0.90, at 2nd week, the score was 
44.92 ± 0.65, at 6th week, the 
score was 36.49 ± 0.74 and at 
the end of 3rd month, the mean 
score was 25.15 ± 1.20, 
respectively. There was 
significant reduction in MDS-
UPDRS score, when compared 
with different follow-ups, p-value 
< 0.05 except baseline versus 2 
weeks, p-value > 0.05. Overall 
the decrease in MDS-UPDRS 




Table 5: Comparison of MDS-UPDRS (part-III) score at different follow-
ups. 
MDS-UPDRS (part-III) Mean S.D Range Minimum Maximum 
At baseline 
(Off Medication) 
45.19 0.90 2.90 44.00 46.90 
At 2 weeks 
(On Medication) 
44.92 0.65 1.90 44.00 45.90 
At 6 weeks 
(On Medication) 
36.49 0.74 2.90 35.10 38.00 
At 3 month 
(On Medication) 
25.15 1.20 4.50 22.50 27.00 
 
 
Table6: Comparison of MDS-UPDRS (part-III) score at different follow-
ups (F-test = 139540.614). 
MDS-UPDRS (part-III) t df p-value 
Baseline versus 2 weeks 0.769 14 0.455 
Baseline versus 6 weeks 26.326 14 < 0.001 
Baseline versus 3 months 53.024 14 < 0.001 
2 weeks versus 6 weeks 43.011 14 < 0.001 
2 weeks versus 12 months 55.032 14 < 0.001 





Figure 3: Graphical Comparison of MDS-UPDRS (part-III) score at 
different follow-ups. 
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 At baseline, the mean MDS – 
UPDRS (part-IV) score was 10.18 
± 0.87, at 2nd week, the score was 
9.83 ± 0.59, at 6th week, the score 
was 5.93 ± 1.43 and at the end of 
3rd month, the mean score was 
3.85 ± 1.03, respectively. There 
was significant reduction in 
MDS-UPDRS score when 
compared with different follow-
ups, p-value < 0.05 except 
baseline versus 2 weeks, p-value 
> 0.05. Overall the decrease in 




Table 7: Comparison of MDS-UPDRS (part-IV) score at different follow-
ups. 
MDS-UPDRS (part-IV) Mean S.D Range Minimum Maximum 
At baseline 10.18 0.87 2.20 9.00 11.20 
At 2 weeks   9.83 0.59 1.80 9.00 10.80 
At 6 weeks   5.93 1.43 3.80 4.20   8.00 




Table 8: Comparison of MDS-UPDRS (part-IV) score at different follow-
ups (F-test = 3552.273). 
MDS-UPDRS (part-IV) t df p-value 
Baseline versus 2 weeks   1.111 14 0.285 
Baseline versus 6 weeks 12.131 14 < 0.001 
Baseline versus 3 months 18.984 14 < 0.001 
2 weeks versus 6 weeks   7.747 14 < 0.001 
2 weeks versus 12 months 15.916 14 < 0.001 






Figure 4: Graphical Comparison of MDS-UPDRS (part-IV) score at 
different follow-ups. 
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PD is an aging disease. Bilateral DBS for advanced 
Parkinsonism is an effective treatment for 
controlling motor symptoms, including motor 
variations and dyskinesia.13 MDS-UPDRS is an 
effective way to determine the effect of motor as 
well as non-motor aspect of the disease process, 
as it’s been documented that there are some 
non-motor symptoms like depression and 
cognition which are also significant. Recently 
Movement Disorder Society has established new 
revised questionnaire.9 The new questionnaire 
measures the efficacy of the treatment more 
precisely.6,9 The MDS-UPDRS Part I, In Parkinson’s 
disease measures the score of non-motor 
symptoms. Another study 7shows improvement in 
MDS UPDRS I. In this study at baseline the mean 
MDS – UPDRS (Part-I) score was 13.8 ± 6.3 and at 
the end of 6 months the mean score was 10.7 ± 
4.7 respectively. 
 In the current study, at baseline, the mean 
MDS – UPDRS (Part-I) score was 14.20 ± 0.61 and 
at the end of 3rd month the mean score was 11.18 
± 0.47, respectively. Overall the decrease in MDS-
UPDRS score (Part-I) was statistically significant 
(Tables 1 & 2). 
 Chou et al 7 showed animprovement in MDS 
UPDRS II. In this study, at baseline the mean 
MDS – UPDRS (Part-II) score was 18.4 ± 8 and at 
the end of 6 months the mean score was 13.4 ± 
16.6, respectively. 
 In the current study, at baseline, the mean 
MDS – UPDRS (part-II) score was 18.99 ± 0.70 and 
at the end of 3rd month, the mean score was 
13.01 ± 0.57, respectively.  Overall, the decrease 
in MDS-UPDRS score (Part-II) was statistically 
significant (Tables 3 & 4). 
 Another study shows UPDRS III after STN 
stimulation procedure and on medications was 
reduced to 15.9 ± 12.2 at one year follow-up 
while on baseline it was 56.7 ± 15.7.8 
 Chou et al7 showed an improvement in MDS 
UPDRS III. In this study at baseline the mean 
MDS – UPDRS (Part-III) score was 45.6 ± 16.6 (Off 
Medication) and at the end of 6 months, the 
mean score was 25.3 ± 12.5 (On stimulation/On 
Medication) respectively. 
 In comparison to our study, at baseline, the 
mean MDS – UPDRS (part-III) score was 45.19 ± 
0.90 (off Medication) and at the end of 3rd month, 
the mean score was 25.15 ± 1.20 (On Medication). 
Overall, the decrease in MDS-UPDRS score (Part-
III) was statistically significant (Tables 5 & 6). 
 Chou et al7 observed an improvement in MDS 
UPDRS IV. In this study, at baseline, the mean 
MDS – UPDRS (Part-IV) score was 9.6 ± 4.4 and at 
the end of 6 months, the mean score was 2.5 ± 
2.3, respectively. 
 At baseline, the mean MDS – UPDRS (part-IV) 
score was 10.18 ± 0.87 and at the end of 3rd 
month, the mean score was 3.85 ± 1.03 
respectively, (Tables 7 & 8). Overall, the decrease 
in MDS-UPDRS score. 
 Regarding complication in our study, there 
was one patient (6.67%) who hadan intracerebral 
hemorrhage which resolved over a month. It was 
picked-up by the neurologist with deterioration 
of the power and the procedure was abandoned. 
 Levi et al. (2015)16 reported that the 90-day 
post-operative mortality rate was 0%. Incidence 
of complications related to surgery was 6, (54%). 
In the elderly group, they observed 3 post-
operatives ICH 7, (89%), 1 requiring urgent 
surgical evacuation. In the younger group, 2 post-
operative asymptomatic ICH 2, (89%) and 2 
wound infections 2, (89%). 
 As per Kim et al (2017),3 the infection 
occurred in 5% of all DBS medical procedures and 
in 7% of all PD patients who underwent DBS. 
Most Infections (75%) were within 3 months after 
the DBS procedure.Gram-positive microscopic 
organisms were the most widely recognized 
pathogens (75%). 
 In an investigation done by Fernández-Pajarín, 
et al (2017),15 it was found that the pulse 
generator being the most widely recognized area 
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for infection. Lead breaks (9.3%) are the second 
most common complexity. Symptomatic peri-lead 
edema and blister formation were extraordinary. 
 In our study of Parkinson disease, patients 
significantly improved after bilateral STN DBS not 
only in their motor component, but also the non-
motor components which improved their quality 
of life. In our study, we used a MDS UPDRS 
scoring system previously there was the UPDRS 
scoring system, which is more popular but, the 
drawback is that it addresses more motor 
symptoms as compared to non-motor symptoms 
of the disease. In our study, there are certain 
limitations which include a less number of 
patients, which is definitely due to the cost of the 
procedure and secondly, we assessed post-
operative patient with stimulation and on 
medications as patient were reluctant to off their 
stimulation after getting beneficial effect so we 
have to assess patient on Med/On Stim. With the 
help of neurologist we followed the patient well. 
 Beyond the scope of this study, we also found 
that with STN DBS the dosage requirement of the 
Anti-Parkinson’s medicines were reduced 
significantly. Those Patients who presented with 
drug related Dyskinesia specially got benefited by 
the STN DBS due to a reduction in the doses. 
 This study encouraging for the treatment of 
advanced Parkinson’s disease surgically as 
patients showed significant improvement in both 




It is concluded that deep brain stimulation (DBS) 
improved symptoms, as assessed by the 
reduction in MDS-UPDRS. And also the need for 
medications is reduced (but they are required). 
Hence, this procedure should be opted for such a 
significant health issue to improve the symptoms 
in our setups. 
 
REFERENCES 
1. Elbaz A, Carcaillon L, Kab S.Moisan F. Epidemiology 
of Parkinson's disease. Rev Neurol. 2016; 172: 14-
26. 
2. Chen, S-Y, Tsai, S-T. The Epidemiology of 
Parkinson's Disease. Tzu ChiMedical Journal, 2010; 
22: 73-81. 
3. Pouratian N, Thakkar, S Kim, W  Bronstein, J. M. 
Deep brain stimulation for the treatment of 
Parkinson’s disease efficacy and safety. 
Degenerative Neurol Neuromuscular Dis, 2012: 1-
16. 
4. Benabid AL, Chabardes S. SeigneuretE. Deep-brain 
stimulation in Parkinson's disease: long-term 
efficacy and safety – What happened this year? 
Curr Opin Neurol. 2005; 18: 623-30. 
5. Follett K. A, Weaver F. M, Stern M, Hur K, Harris, C. 
L Luo, P.Marks Jr, W. J. Rothlind, J. Sagher, O. Moy 
C. Pallidal versus subthalamic deep-brain 
stimulation for Parkinson's disease. N Engl J Med. 
2010; 362: 2077-2091. 
6. Fahn S. Unified Parkinson's disease rating scale. J 
Parkinsons Dis. 1987. 
7. Kelvin L. Chou, Jennifer L. Taylor, Parag G. Patil, 
The MDS–UPDRS tracks motor and non–motor 
improvement due to subthalamic nucleus deep 
brain stimulation in Parkinson disease 
Parkinsonism Relat Disord. 2013; 19 (11). 
8. Rodriguez-Oroz, M Obeso, J Lang, Houeto, J.-L, 
Pollak, P. Rehncrona, et al. Bilateral deep brain 
stimulation in Parkinson's disease: a multicentre 
study with 4 years follow-up. Brain, 2005; 128: 
2240-2249. 
9. Goetz CG. Tilley BC. Shaftman SR. Stebbins GT, 
Fahn, S. et al. Movement Disorder Society – 
sponsored revision of the Unified Parkinson's 
Disease Rating Scale (MDS – UPDRS): scale 
presentation and clinimetric testing results. Mov 
Disord. 2008; 23: 2129-2170. 
10. Zesiewicz T. Sullivan, K. Arnulf, I. Chaudhuri, K. 
Morgan JC, et al.W Practice parameter: treatment 
of nonmotor symptoms of Parkinson disease 
report of the quality standards subcommittee of 
the american academy of neurology. Neurology, 
2010; 74: 924-931. 
11. Jafari, N. Pahwa, R. Nazzaro, J. M. Arnold, P. M. 
Lyons K. E. MDS-UPDRS to assess non-motor 
symptoms after STN DBS for Parkinson's disease. 
Khalid Mahmood, et al: Outcome of Deep Brain Stimulation (DBS) for the Treatment of Parkinson’s Disease in Terms 
 
http//www.pakjns.org         Pak. J. of Neurol. Surg. –2020 – 24 (4): 305-314.        314   
 
International Journal of Neuroscience, 2016; 126: 
25-29. 
12. Krause M, Fogel W Heck, A Hacke, W Bonsanto, M 
Trenkwalder, C. Tronnier V. Deep brain stimulation 
for the treatment of Parkinson's disease: 
subthalamic nucleus versus globus pallidus 
internus. J Neurol Neurosurg Psychiatry, 2001; 70: 
464-470. 
13. Castrioto A. Lozano AM. Poon  Y-Y. Lang A., Fallis 
M, Moro E. Ten-year outcome of subthalamic 
stimulation in Parkinson disease: a blinded 
evaluation. Arch Neurol. 2011; 68: 1550-1556. 
14. Ashis Kumar, Kakkar, Neha Dahiya, Management 
of Parkinson’s Disease: Current and future 
Pharmacotherapy. Eur J Pharmac. 2015; 750: 74-81. 
15. Fernández FS, Alvarez Vega MA, Antuña Ramos A, 
Fernández González F, Lozano Aragoneses B. Lead 
fractures in deep brain stimulation during long-
term follow-up. Parkinson’s Disease, 2010; 2010. 
16. Levi V, Carrabba G, Rampini P, Locatelli M. Short 
term surgical complications after subthalamic deep 
brain stimulation for Parkinson’s disease: does old 





Disclosures:  Authors report no conflict of interest. 
Ethical Review Board Approval:  The study was conformed to the ethical review board requirements. 
Human Subjects:  Consent was obtained by all patients/participants in this study. 
Conflicts of Interest: 
In compliance with the ICMJE uniform disclosure form, all authors declare the following: 
Financial Relationships:  All authors have declared that they have no financial relationships at present or within 
the previous three years with any organizations that might have an interest in the submitted work. 
Other Relationships:  All authors have declared that there are no other relationships or activities that could 






Sr.# Author’s Full Name Intellectual Contribution to Paper in Terms of: 
1. Khalid Mahmood 1. Study design and methodology. 
2. Omair Afzal Ali 2. Paper writing, referencing, and data calculations. 
3. Adeeb-ul-Hassan 3. Data collection and calculations. 
4. Imran Ali 4. Analysis of data and interpretation of results. 
 
 
 
